Contributions
Abstract: P1042
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: To assess differences in resting-state functional connectivity (FC) between distinct morphologic MRI-phenotypes in multiple sclerosis (MS).
Methods: From a prospective MRI study, we identified MS patients with high T2-lesion load (mean 20.4 cm3) and high normalized brain volume (NBV: mean 1586.2 cm3; both defined by median-split) as a primarily inflammatory group (IG; N=22) and a primarily neurodegenerative group (NG; N=42) consisting of patients with low T2-lesion load (mean 6.8 cm3) and low NBV (mean 1480.9 cm3). Independent component analysis of resting-state fMRI was used to assess potential differences in FC of the visual, default-mode and sensorimotor network.
Results: The two groups did not differ regarding EDSS (IG median EDSS= 1.0; NG median EDSS= 1.5), disease duration (DD; IG 4.0 vs NG 3.5 years) and distribution of clinical phenotypes (41% CIS in both groups). Patients of the IG showed significantly higher FC in the sensorimotor network compared to patients in the NG, even after correcting for sex- and age-differences. Only in the IG, higher EDSS scores and T2-lesion load were associated with lower connectivity in the sensorimotor network. In both groups no correlation between FC and NBV was observed.
Conclusions: Multiple sclerosis patients with distinct MRI-phenotypes defined by morphological changes show differences in brain function linked to EDSS scores and T2-lesion load.
Disclosure:
Daniela Pinter receives funding from the Austrian Science fund (T 690- B23) and has received funding for travel from Merck and funding from Genzyme/Sanofi-Aventis.
Christian Beckmann gratefully acknowledges funding from the Wellcome Trust UK Strategic Award [098369/Z/12/Z] and is supported by the Netherlands Organisation for Scientific Research (NWO-Vidi 864-12-003). CFB receives research funding from Pfizer (Inc.) and is Director and shareholder of SBGneuro Ltd.
Franz Fazekas serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, D-Pharm Ltd., and Teva Pharmaceutical Industries Ltd./sanofi-aventis; serves on the editorial boards of Cerebrovascular Diseases, Multiple Sclerosis, the Polish Journal of Neurology and Neurosurgery, Stroke, and the Swiss Archives of Neurology and Psychiatry; and has received speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, and sanofi-aventis.
Michael Khalil has received funding for travel and speaker honoraria from Bayer Schering Pharma, Novartis Genzyme, Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd. and a research grant from Teva Pharmaceutical Industries Ltd.
Alexander Pichler reports no disclosures.
Stefan Ropele reports no disclosures.
Siegrid Fuchs serves on scientific advisory boards and / or has received speaker honoraria from Biogen Idec, Merck, Novartis; Roche, TEVA Pharmaceutical Industries and Sanofi-Aventis.
Christian Enzinger received funding for traveling and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd./sanofi-aventis, Shire; received research support from Merck Serono, Biogen Idec, and Teva Pharmaceutical Industries Ltd./sanofi-aventis; and serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Genzyme, Roche, and Teva Pharmaceutical Industries Ltd./sanofi- Aventis.
Abstract: P1042
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Objective: To assess differences in resting-state functional connectivity (FC) between distinct morphologic MRI-phenotypes in multiple sclerosis (MS).
Methods: From a prospective MRI study, we identified MS patients with high T2-lesion load (mean 20.4 cm3) and high normalized brain volume (NBV: mean 1586.2 cm3; both defined by median-split) as a primarily inflammatory group (IG; N=22) and a primarily neurodegenerative group (NG; N=42) consisting of patients with low T2-lesion load (mean 6.8 cm3) and low NBV (mean 1480.9 cm3). Independent component analysis of resting-state fMRI was used to assess potential differences in FC of the visual, default-mode and sensorimotor network.
Results: The two groups did not differ regarding EDSS (IG median EDSS= 1.0; NG median EDSS= 1.5), disease duration (DD; IG 4.0 vs NG 3.5 years) and distribution of clinical phenotypes (41% CIS in both groups). Patients of the IG showed significantly higher FC in the sensorimotor network compared to patients in the NG, even after correcting for sex- and age-differences. Only in the IG, higher EDSS scores and T2-lesion load were associated with lower connectivity in the sensorimotor network. In both groups no correlation between FC and NBV was observed.
Conclusions: Multiple sclerosis patients with distinct MRI-phenotypes defined by morphological changes show differences in brain function linked to EDSS scores and T2-lesion load.
Disclosure:
Daniela Pinter receives funding from the Austrian Science fund (T 690- B23) and has received funding for travel from Merck and funding from Genzyme/Sanofi-Aventis.
Christian Beckmann gratefully acknowledges funding from the Wellcome Trust UK Strategic Award [098369/Z/12/Z] and is supported by the Netherlands Organisation for Scientific Research (NWO-Vidi 864-12-003). CFB receives research funding from Pfizer (Inc.) and is Director and shareholder of SBGneuro Ltd.
Franz Fazekas serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, D-Pharm Ltd., and Teva Pharmaceutical Industries Ltd./sanofi-aventis; serves on the editorial boards of Cerebrovascular Diseases, Multiple Sclerosis, the Polish Journal of Neurology and Neurosurgery, Stroke, and the Swiss Archives of Neurology and Psychiatry; and has received speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, and sanofi-aventis.
Michael Khalil has received funding for travel and speaker honoraria from Bayer Schering Pharma, Novartis Genzyme, Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd. and a research grant from Teva Pharmaceutical Industries Ltd.
Alexander Pichler reports no disclosures.
Stefan Ropele reports no disclosures.
Siegrid Fuchs serves on scientific advisory boards and / or has received speaker honoraria from Biogen Idec, Merck, Novartis; Roche, TEVA Pharmaceutical Industries and Sanofi-Aventis.
Christian Enzinger received funding for traveling and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd./sanofi-aventis, Shire; received research support from Merck Serono, Biogen Idec, and Teva Pharmaceutical Industries Ltd./sanofi-aventis; and serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Genzyme, Roche, and Teva Pharmaceutical Industries Ltd./sanofi- Aventis.